Sernova (SVA) Competitors C$0.19 -0.01 (-5.00%) As of 08/1/2025 03:38 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock SVA vs. ABCN, EMC, FRX, BCT, IPA, TH, ONC, SCYB, COM, and NVHShould you be buying Sernova stock or one of its competitors? The main competitors of Sernova include VIVO Cannabis (ABCN), Emblem (EMC), Fennec Pharmaceuticals (FRX), BriaCell Therapeutics (BCT), ImmunoPrecise Antibodies (IPA), Theratechnologies (TH), Oncolytics Biotech (ONC), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), and Novoheart (NVH). These companies are all part of the "biotechnology" industry. Sernova vs. Its Competitors VIVO Cannabis Emblem Fennec Pharmaceuticals BriaCell Therapeutics ImmunoPrecise Antibodies Theratechnologies Oncolytics Biotech Scythian Biosciences 138267 (COM.TO) Novoheart VIVO Cannabis (CVE:ABCN) and Sernova (TSE:SVA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations. Does the media prefer ABCN or SVA? In the previous week, VIVO Cannabis' average media sentiment score of 0.00 equaled Sernova'saverage media sentiment score. Company Overall Sentiment VIVO Cannabis Neutral Sernova Neutral Do insiders and institutionals hold more shares of ABCN or SVA? 0.1% of Sernova shares are held by institutional investors. 12.1% of Sernova shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts rate ABCN or SVA? Sernova has a consensus price target of C$2.00, suggesting a potential upside of 952.63%. Given Sernova's stronger consensus rating and higher probable upside, analysts plainly believe Sernova is more favorable than VIVO Cannabis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VIVO Cannabis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Sernova 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Which has higher valuation & earnings, ABCN or SVA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVIVO CannabisN/AN/AN/AN/AN/ASernovaN/AN/A-C$35.70M-C$0.10-1.83 Is ABCN or SVA more profitable? Sernova's return on equity of 473.85% beat VIVO Cannabis' return on equity.Company Net Margins Return on Equity Return on Assets VIVO CannabisN/A N/A N/A Sernova N/A 473.85%-119.26% SummarySernova beats VIVO Cannabis on 7 of the 8 factors compared between the two stocks. Get Sernova News Delivered to You Automatically Sign up to receive the latest news and ratings for SVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SVA vs. The Competition Export to ExcelMetricSernovaBiotechnology IndustryMedical SectorTSE ExchangeMarket CapC$63.93MC$136.44MC$5.51BC$6.20BDividend Yield7.86%3.74%4.74%6.72%P/E Ratio-1.833.7829.1763.43Price / SalesN/A4,423.95435.421,250.99Price / Cash6.1513.1924.4883.29Price / Book-4.4538.748.494.86Net Income-C$35.70M-C$90.99MC$3.24BC$301.20M7 Day Performance-5.00%-1.90%0.63%-2.11%1 Month Performance22.58%3.49%7.95%0.22%1 Year Performance-28.30%177.21%30.47%26.44% Sernova Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SVASernova1.9492 of 5 starsC$0.19-5.0%C$2.00+952.6%-28.3%C$63.93MN/A-1.831,959ABCNVIVO CannabisN/AC$1.32+5.6%N/A+0.0%C$256.62MN/A0.00N/AGap UpEMCEmblemN/A$1.88+1.6%N/A+0.0%$245.45M$5.71M-9.89N/AFRXFennec PharmaceuticalsN/AC$11.72-2.3%N/A+38.0%C$226.02MC$34.86M-198.5310Gap DownBCTBriaCell TherapeuticsN/AC$10.60-3.8%C$15.00+41.5%+0.0%C$168.68MN/A-28.195IPAImmunoPrecise AntibodiesN/AC$6.50+0.8%N/A+0.0%C$162.08MC$19.47M-7.3080Gap DownTHTheratechnologiesN/AC$4.35+0.2%N/A+129.6%C$138.79MC$52.22M-49.24103ONCOncolytics Biotech1.2328 of 5 starsC$1.41-6.6%C$3.50+148.2%-2.1%C$108.67MN/A-3.9329Gap DownSCYBScythian BiosciencesN/AC$3.49-5.9%N/A+0.0%C$102.38MN/A0.00N/AHigh Trading VolumeCOM138267 (COM.TO)N/AN/AN/AN/AC$102.19MN/A0.00N/ANVHNovoheartN/AC$0.53+1.9%N/A+0.0%C$99.98MC$423.50K-13.95N/A Related Companies and Tools Related Companies VIVO Cannabis Alternatives Emblem Alternatives Fennec Pharmaceuticals Alternatives BriaCell Therapeutics Alternatives ImmunoPrecise Antibodies Alternatives Theratechnologies Alternatives Oncolytics Biotech Alternatives Scythian Biosciences Alternatives 138267 (COM.TO) Alternatives Novoheart Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (TSE:SVA) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredLeaked Gov’t Memo Reveals $100 Trillion DeadlineOnly Days Left to Claim Your Share of Trump's $100T Play Trump's economic blueprint is about to go live, an...Stansberry Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sernova Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sernova With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
